RECOMMENDATIONS CONCERNING DEVELOPMENT OF THE SCALE OF BUDGET IMPACT RATE IN THE EVALUATION OF THE PURCHASE OF MEDICINES IN UKRAINE
DOI:
https://doi.org/10.11603/2312-0967.2019.3.10402Keywords:
health technology assessment, budget impact rate, national list of essential medicines, medicinesAbstract
The aim of the work. Development of a rate of budget impact when evaluating the inclusion of a medicines on the National List of Essential Medicines (National List) in the analysis of the economic efficiency.
Materials and methods. ABC analysis used for developed of this recommendations. The aim is assessing of the potential impact on the budget of medicines in case of its inclusion on the National List. The study used data provided by the Pharmexsplorer market research system, Support in Market Development (SMD) for 2018.
Results and discussion. The developed of scale of rate of budget impact is recommended to be used to assess the financial consequences of using medical technology over an appropriate time horizon of 1 year or more to ensure an adequate level of functioning in the healthcare sector. In the case of procurement by state budget and local budgets, if expenses per one INN exceeds 40 million UAH per year, the budget impact rate is excessive. If the expenses for one INN are in the range from 20 million to 40 million, the budget impact rate is big, if the costs range from 10 to 20 million UAH, then the impact is moderate, if expenses are less than 10 million, then the impact is insignificant.
Subject to the inclusion of a medicinal product in the National List, in the case of procurement by health care institutions that are financed from the local budget, the scale of budget impact levels has the following gradation: if the cost per INN exceeds 17 million UAH per year, the budget impact rate is excessive. If the expenses for one INN are in the range from 6 to 17 million UAH, the budget impact rate is big, if the expenses for one INN are in the range from 3 to 6 million UAH, the impact is moderate; if the expenses are less than 3 million, the impact is insignificant.
Conclusion. A scale for determining of rate of budget impact was developed based on the analysis of the procurement of medicines from the National List for 2018. It has such a gradation in four levels of influence: excessive, big, moderate and insignificant. It is promising to use a rate of budget impact for HTA with the aim of future financing by the expenses of state and local budgets in Ukraine.
References
Decree of the Cabinet of Ministers 12/05/2018 р. № 1022. On Approval of the State Strategy for the Implementation of the State Policy of Providing the Population with Medicines for the period up to 2025 [Про затвердження Державної стратегії реалізації державної політики забезпечення населення лікарськими засобами на період до 2025 року]. Available from: [https://zakon.rada.gov.ua/laws/show/1022-2018-%D0%BFhttps://zakon.rada.gov.ua/laws/show/z0258-16]
Order of the Ministry of Health of Ukraine 02/11/2016 № 84. On Approval of the Regulation on the National List of Essential Medicines and the Regulation of the Expert Committee of Selection and Use of Essential Medicines [Про затвердження Положення про Національний перелік основних лікарських засобів та Положення про експертний комітет з відбору та використання основних лікарських засобів] Available from: [ https://zakon.rada.gov.ua/laws/show/z0258-16]
Guidelines for the health technology assessment, Expert Committee on the selection and use of essential medicines of the Ministry of Health of Ukraine, Version 1.1., Kyiv 2018. [Керівна настанова із оцінки технологій охорони здоров’я, Експертний комітет з відбору та використання основних лікарських засобів МОЗ України, Версія 1.1.] Київ 2018.
Order of the Ministry of Health of Ukraine on 04/03/2017. № 275-р. On approval of the medium-term plan of the Government's priority actions by 2020 and the plan of the Government's priority actions for 2017. [Про затвердження середньострокового плану пріоритетних дій Уряду до 2020 року та плану пріоритетних дій Уряду на 2017 рік] Available from: [https://zakon.rada.gov.ua/laws/show/275-2017-%D1%80#n10]
Budget impact test (NICE). Access [https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/budget-impact-test]
Sean D. Sullivan, Josephine A. Mauskopf, Federico Augustovski, J. Jaime Caro, Karen M. Lee, Mark Minchin, et al. - Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health. 2014; Vol.17, Issue 1: 5–14. Available from: [https://doi.org/10.1016/j.jval.2013.08.2291] DOI: https://doi.org/10.1016/j.jval.2013.08.2291
Josephine A. Mauskopf, Sean D. Sullivan, Lieven Annemans, Jaime Caro, C. Daniel Mullins, Mark Nuijten, at al. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices— Budget Impact Analysis. Value in Health. 2007; Vol.10, № 5: 336-347. Available from: [https://doi.org/10.1111/j.1524-4733.2007.00187.x] DOI: https://doi.org/10.1111/j.1524-4733.2007.00187.x
Drug and Therapeutics Committees - A Practical Guide. World Health Organization. 2003; Available from: [ http://apps.who.int/medicinedocs/es/d/Js4882e/12.html]
Management Sciences for Health and World Health Organization. 2007. Drug and Therapeutics Committee Training Course. Submitted to the U.S. Agency for International Development by the Rational Pharmaceutical Management Plus Program. Arlington, VA: Management Sciences for Health.
Pariy VD, Safonov YuM, Zakharova NM, Dumenko TM, Zhula AV, Taran VV., Borus VM, Vezhnovets TA, Matukova DG, Prus NV. Economichnuy analis vukorustannia resursiv v sustemi okhoronu zdorovia [Economic analysis of the use of resources in the health system] Zhutomur: «Polissia»; 2015. 142 p.
Morozov A. M.., Yakovleva L. V.., Besditko N. V. et al. Metoduchni recomendacii z ocincuclinichnoi ta economichnoi docilnosti vucorustannia likarskukh zasobiv v licuvalno-profilactuchnomu zacladi (suprovid formularnoi sustemu) [Methodical recommendations for assessing the clinical and economic feasibility of the use of drugs in the health care institution (support of the formular system)]. – Kharkiv: NPhU, 2012. – 59 s.
Bidiuk PI, Terentiev OM, Prosiankina-Zharova TI. Prukladna statistika [Applied statistics] Vinnutsia: "Edelveis &K"; 2013.
Gerasumenko SS, Golovach AV, Jerina AM, Kozuriev OV, Palian ZO, Shustiko AA. Statistika 2-Ed, К.: КNЕU; 2000. 467 p.
Downloads
Published
How to Cite
Issue
Section
License
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
